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Available online 7 January 2015AbstractDespite substantial investment in prevention, treatment and aftercare, cancer remains a leading cause of death worldwide. More effective and
accessible therapies are required. A potential solution is the use of endospore forming Clostridium species, either on their own, or as a tumour
delivery vehicle for anti-cancer drugs. This is because intravenously injected spores of these obligate anaerobes can exclusively germinate in the
hypoxic/necrotic regions present in solid tumours and nowhere else in the body. Research aimed at exploiting this unique phenomenon in anti-
tumour strategies has been ongoing since the early part of the 20th century. Only in the last decade, however, has there been significant progress
in the development and refinement of strategies based on spore-mediated tumour colonisation using a range of clostridial species. Much of this
progress has been due to advances in genomics and our ability to modify strains using more sophisticated gene tools.
© 2015 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Cancer is a broad term for a class of diseases characterised
by uncontrolled cell division, leading to abnormal growth. In a
normal cell there is a finely regulated balance between all
signals promoting or restraining growth. In tumour cells,
however, this balance is disrupted. The great proportion of all
abnormalities which occur in organisms are triggered either by
inherited genetic predispositions, environmental factors or
exposure to certain chemicals or harmful conditions which
alter the genomic structure and processes [1,2]. According to
the World Health Organisation it was reported that for 2012
there were 14 million new cancer cases occurring worldwide,
which contributed to around 8.2 million deaths. It is predicted
that within the next 15 years the burden of cancer will increase
to 23.6 million.* Corresponding author.
E-mail address: nigel.minton@nottingham.ac.uk (N.P. Minton).
http://dx.doi.org/10.1016/j.resmic.2014.12.006
0923-2508/© 2015 The Authors. Published by Elsevier Masson SAS on behalf of I
creativecommons.org/licenses/by/4.0/).To date, there is no single treatment for cancer. There are
different ways to treat cancer, including surgery, radiotherapy,
chemotherapy, hormone therapy, and immunotherapy. These
approaches are effective in the management of many cases, but
it can be difficult to control tumours in some patients, and
produce a favourable outcome.
Cancer treatments currently in use suffer from number of
limitations. Chemotherapy regimes typically result in un-
pleasant physical side effects (nausea, impotence), increased
risk of developing other types of cancer and mild cognitive
impairments [3]. Thus, medical and scientific research inves-
tigating new anti-cancer strategies continues.
A particularly innovative approach that is less collateral to
patient’ general health and well-being is gene therapy.
Although, still nascent, this new group of treatments might
bring more targeted (specific) approach to treat a specific
cancer type and provide better cure than the standard
methods.
The concept of using proteins as anti-cancer agents has
led to a multitude of strategies reliant on the use of toxins,nstitut Pasteur. This is an open access article under the CC BY license (http://
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invariably highly effective against tumour cell lines, the
more exigent problem remains their selective delivery into
the tumour mass. Accordingly, much of the focus of gene
therapy research has been devoted to the derivation and
testing of tumour delivery vehicles, most notably antibody-
based, viral, non-viral or non-biological delivery systems.
Their characteristics and specificities, as well as advantages
and drawbacks, have been the subject of a number of re-
views [4e6]. Nevertheless, it is worth noting that these
delivery strategies have created concerns over universality,
safety and development costs. Additionally, the low success
rate of these delivery vehicles to selectively target the
microenvironment of a tumour is a key reason that many
studies have been terminated after stages I or II of clinical
trials.
2. Targeting tumour hypoxia
It's estimated that more than 80% of cancers are classified
as solid tumours [7]. The majority of these contain large re-
gions of poorly oxygenated tissue, known as hypoxia. These
hypoxic tumour tissues occur due to a persistent imbalance
between the oxygen being delivered to the tumour through
blood microvessels and that being consumed by proliferating
cancer cells. In addition, some solid tumours are found to have
necrotic (dead) cores, a direct effect of long-standing tissue
hypoxia [8,9].
Tumour hypoxia has been demonstrated to reduce the ef-
ficacy of many standard cytotoxic drugs used in the treatment
of cancer [10]. This is due to ineffective penetration of the
drug into the hypoxic mass of the tumour, due to poor vas-
cularisation. A chosen drug concentration may be inadequate
for the destruction of the more distant, more hypoxic cells in
the interior of the tumour.
Growing evidence suggests hypoxia acts as a prognostic for
patient survival and cancer control [11]. The study of Nods-
mark et al. produced evidence supporting the idea that tumour
hypoxia was linked with a negative prognosis in 397 patients
examined with advanced head and neck cancer following
primary radiotherapy [12]. Similar findings were found for
soft tissue sarcomas and cervix cancers [13,14].
Cancer survival prognosis is strongly related to the devel-
opment of metastatic disease. It is estimated that around 90%
of cancer-related deaths are linked to metastatic spread
[15,16]. Hypoxia plays a key role in metastatic progression
[11,17]. This is mainly due to chaotic angiogenesis of new
blood vessels that alters the tissue microenvironment, the
hypoxia-stimulated expression of pro-metastatic genes or
hypoxia-triggered mutagenesis of p53 gene [11].
Patients diagnosed and surgically treated for primary tu-
mours with severe hypoxia have a much lower chance of
disease-free survival. There is a strong likelihood that metas-
tasis has been initiated, which goes undetected at the time of
surgery [13].
The challenge of hypoxia has provided opportunities for
novel tumour therapies [11]. The presence of tissue withsignificantly reduced levels of oxygen and necrosis are
unique to solid tumours. This can be exploited as a niche
environment for cancer therapies. Certain novel strategies
involve the use of hypoxia-activated prodrugs or develop-
ment of HIF-1 inhibitors. A particularly promising option is
the use of anaerobic bacteria. An oxygen-free environment
creates ideal conditions for certain microbes, such as Clos-
tridium spp., to colonise and target a necrotic/hypoxic
growth. Such a therapy could potentially be used to treat
relatively small tumours, preventing further development of
hypoxic cancer tissue and the subsequent metastatic
progression.
3. A brief historical overview on clostridial oncolysis3.1. The use of clostridia species as a tool in cancer
therapyThe genus Clostridium is one of the largest prokaryotic
genera, consisting of more than 130 physiologically diverse
Gram-positive bacterial species. They are obligate, rod-shaped
anaerobes and, in common with the aerobic genus Bacillus,
produce endospores in order to survive adversity [18].
As a grouping, Clostridium is, in the main, composed of
entirely benign, non-pathogenic species that are widely
distributed in the environment. Nonetheless, they are best
known for the pathogenic properties of a handful of species. It
is the attributes of the non-pathogenic members, however,
which may ultimately be of most significance to mankind [19].
In particular, it is the ability of clostridial endospores to
infiltrate, and hence selectively germinate in, the hypoxic re-
gions of solid tumours that may have the greatest impact
[20,21]. The history of the application of clostridial spores in
cancer therapies has been broadly reviewed in a number of
scientific publications [22e26]. Some of the most crucial
findings, which laid the foundation for the most recent ad-
vances in clostridial tumour therapy, are briefly outlined in
Box 1.
To avoid the use of pathogenic species, such as Clostridium
histolyticum and Clostridium tetani, the use of Clostridium
butyricum M-55 was investigated by M€ose and M€ose in 1959.
Significant oncolytic effects were observed after injecting
spores into animals and later into human patients [27e29].
Thanks to these properties, the strain was named Clostridium
oncolyticum and later reclassified as Clostridium sporogenes
M-55 (ATCC 13732). Saccharolytic clostridia such as Clos-
tridium beijerinckii or Clostridium acetobutylicum were also
investigated and proved to be effective in tumour colonisation.
However, compared to C. sporogenes the reproducibility of
colonisation was inferior. Moreover, the total number of
vegetative cells present in a tumour was orders of magnitude
lower than C. sporogenes [30]. The initial benefits of a more
aggressive coloniser have additionally been shown in a study
that utilised a non-toxinogenic strain of Clostridium novyi-NT.
The superior colonisation abilities of C. sporogenes and C.
novyi-NT are likely a consequence of them being proteolytic
species.
Box 1. The historical background of the use of
Clostridium spp in cancer therapies.
The concept of using Clostridium species as
tumour vectors was preceded by a number of
experimental and clinical observations. As early
as 1813, patients diagnosed with cancer were re-
ported to unexpectedly defeat the illness after
suffering from gangrene e infection caused by C.
perfringens [82,83]. Later experiments sought to
deliberately make use of clostridia in treating
cancer. In 1935, Connell injected sterile filtrates of
C. histolyticum containing proteolytic enzymes
directly into tumour tissues as a means of causing
tumour destruction [84]. Thereafter, Parker and
colleagues pursued the concept that injection of
C. histolyticum spores into the transplanted
sarcomas of mice results could cause tumour
regression. These studies resulted in noticeable
lysis of tumour tissues, and represented the first
time that whole Clostridium organisms were
used to bring about tumour regression [85].
The most compelling evidence for the effective-
ness and selectiveness of this strategy for target-
ing tumours was provided by a study using C.
tetani. Spores were injected intravenously as
opposed to directly into the tumour mass. The
tumour bearing animals died (within 48 h) as a
consequence of the production of lethal tetanus
toxin by the actively growing vegetative cells in the
colonised tumours. In contrast, healthy animals
were unaffected by the injection of C. tetani spores,
as they were unable to germinate and grow [86].
To avoid the use of pathogenic species, such as C.
histolyticum and C. tetani, the use of C. butyricum
M-55 was investigated by M€ose and M€ose in
1959. Significant oncolytic effects were observed
after injecting spores into animals and later into
human patients [27e29]. Thanks to these proper-
ties, the strain was named C. oncolyticum and
later reclassified as C. sporogenes M-55 (ATCC
13732). Saccharolytic clostridia such as C. beijer-
inckii or C. acetobutylicum were also investigated
and proved to be effective in tumour colonisation.
However, compared to C. sporogenes the repro-
ducibility of colonisation was inferior. Moreover,
the total number of vegetative cells present in a
tumour was orders of magnitude lower than C.
sporogenes [30]. The initial benefits of a more
aggressive coloniser have additionally been
shown in a study that utilised a non-toxinogenic
strain of C. novyi-NT. The superior colonisation
abilities of C. sporogenes and C. novyi-NT are
likely a consequence of them being proteolytic
species.
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CDEPTAs described in the previous section, whilst the use of the
spores of unadulterated Clostridium strains showed great
promise in controlling tumour growth, it was soon realised that
more substantive effects were likely to accrue if combined
with some other form of noxia. One particularly promising
approach was to combine their use with that of prodrug-drug
combinations.
An ideal cancer therapy should only target tumour cells,
leaving healthy tissues unaffected. This can be achieved by
using a harmless circulatory prodrug (pro-agent) that is con-
verted to a highly toxic drug only within the tumour vicinity
through the activity of a prodrug converting enzyme (PCE)
that is specifically localised to the tumour. Such a strategy has
been termed Directed Enzyme Prodrug Therapy (DEPT). It
provides a simple practical solution to the issue of selectively
exposing cancer cells to effective doses of drug that patients
can tolerate [31,32].
DEPT research, to date, has focused on the discovery and
formulation of effective prodrug-drug combinations and the
PCEs that catalyse their conversion. One notable prodrug is
CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] which was
found to inhibit the growth of a Walker rat carcinoma 256 cell
line, yet was inactive against other, and in particular human,
tumour cells [33]. It transpired that Walker 256 tumour cells
produced a unique DT-diaphorase activity, not present in the
other rodent and human cell lines tested, that activated
CB1954 by reduction of its auxochromic nitro groups. The
hydroxylamine produced is cancerostatic because it promotes
the formation of interstrand C8-O6 DNA cross-links, which
are ineffectively repaired by the cell [34,35]. The rat ‘DT-
diaphorase’ is systematically named NQO1 (NAD(P)H:qui-
nine oxidoreductase). Since its discovery, a number of bacte-
rial enzymes able to activate CB1954 have also been
discovered and characterised [36], including a NAD(P)H-
dependent quinone reductases from Escherichia coli (NfnB)
and Bacillus amyloliquefaciens (YwrO). One of the most
important features of DEPT strategies prodrug is the high
therapeutic dose of the converted drug, achieved exclusively
within the vicinity of the tumour. Each enzymatic molecule
can generate large quantities of toxic derivative. In addition,
neighbouring cells not exposed to the drug can display a
similar response, a phenomenon called ‘bystander effect’
[37,38].
The discovery, isolation and subsequent improvements of
other PCEs continue to be pursued in parallel with the appli-
cation of the most suitable delivery systems. Those originally
employed were based either on the fusion of the PCE to a
tumour specific antibody (Antibody-Directed Prodrug Ther-
apy, ADEPT) or on the delivery of the gene encoding the PCE
using viral or non-viral vectors (Gene-Directed Enzyme Pro-
drug Therapy, GDEPT). The concept of using clostridia
(‘Clostridial-Directed Enzyme Prodrug Therapy, CDEPT)’ is a
more recent addition (Fig. 1) to the DEPT arsenal [39,40]. A
summary of the studies published on engineered clostridial
Fig. 1. Mechanism of Clostridial-Directed Enzyme Prodrug Therapy (CDEPT)
utilising C. sporogenes engineered spores as a delivery vector. Briefly, a
nitroreductase gene (PCE) is expressed and integrated into the chromosome of
C. sporogenes. Spores of the therapeutic strain are being prepared in com-
mercial environments and injected into tumour-bearing animal. After tumour
colonisation, a prodrug is delivered. Inside the tumour upon the spore
germination, the expressed PCE subsequently converts the prodrug into a
cytotoxic derivative destroying cancer cells.
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findings until 2003 are presented in Table 1. Here we review
progress since this date.
4. The last decade of research on clostridia in cancer
therapy4.1. The search for better prodrugsAlthough its potential as a therapeutic drug has been
demonstrated in multiple preclinical studies [41e43], CB1954
prodrug has a number of significant limitations that pose
questions about its use in CDEPT. Initial clinical toxicity
studies revealed dose-limiting diarrhoea and liver toxicity in
examined cancer patients. Although the maximum safe dose
was determined as 24 mg/m2, some patients still suffered from
mild diarrhoea, severe nausea and mild reversible trans-
aminase elevation [44]. A study on CB1954 activation re-
ported the prodrug could be metabolised by human hepatic
enzymes. The presence of 2- and 4-hydroxylamines (products
of reduced CB1954) was detected in all three human liver
preparations examined in this study. Significant CB1954
metabolism was observed under atmospheric levels of oxygen,
but was inhibited under hyperoxic conditions [45]. This sug-
gests a risk of clinical hepatotoxicity. Accordingly, this raises
serious concerns around the safe use of CB1954 in therapeutic
treatment. As a result, a lot of effort has been put into the
design and development of more effective equivalents of
CB1954. A promising example is the DNA cross-linking agent
PR-104 [46,47]. This phosphate ester is rapidly converted
in vivo to its cognate alcohol, PR-104A e bioreductive dini-
trobenzamide mustard. In the study by Patterson et al., theanti-tumour effect of CDEPT was enhanced by the use of this
new compound, in conjunction with increased expression of
nitroreductase enzyme (NTR) in C. sporogenes. A new codon
optimised version of an E. coli-derived nitroreductase (sNTR)
was tested, both in vivo and in vitro, in combination with
CB1954 and a novel PR-104. The in vivo study confirmed
20e30 fold higher activity of over-expressed E. coli-NTR with
respect to its original version. In vivo data demonstrated that
sNTR, CB1954 or PR-104 alone resulted in a statistically
insignificant delay in tumour growth. When sNTR was com-
bined either with a single dose of CB1954 (50 mg/kg) or with
three doses of PR-104 (250 mg/kg) over a 3-week period,
much greater anti-tumour activity was observed for both
prodrug/enzyme treatments. A prolonged period of tumour
growth delay (>13 days) was observed [46].
Although it was discovered that PR-104 could also be
converted to its toxic metabolites under oxygenated condi-
tions, the experimental evidence suggests that it offers a
promising alternative to CB1954 in CDEPT approaches [48].
Through microarray analysis of human neoplastic cell lines,
Patterson et al. identified a functional aldo-keto reductase, 1C3
(AKR1C3) that catalysed the reduction of PR-104A. The
possibility of oxygen-based activation and the possibility of
associated risks should be more extensively studied. Never-
theless, the new prodrug and AKR1C3 have also other clinical
potentials. Most recently, PR-104 was applied in a phase Ib
study of patients with advanced solid tumours, and is now in
an ongoing phase II clinical trial, aiming to treat patients with
refractory/relapsed acute leukemia (clinical trial information
NCT01037556) [49]. Although, the expression of AKR1C3
could also be detected in normal tissues, its elevated level in
cancerous environments supports the idea of using AKR1C3
as a marker for detecting PR-104-sensitive tumours.
More recently, a new alternative prodrug, SN 27686, was
tested for activity on HCT116 cell lines, engineered to express
E. coli NTR enzyme [50]. The in vitro results demonstrated
that SN 27686 was 4- to 21-fold more selective than CB1954
in tissue-like cell densities. Moreover, the novel prodrug
exhibited much higher bystander killing efficiency (48% over
only 13% for CB1954) [50]. This study indicates that SN
27686 possesses superior properties compared to CB1954, and
should be tested in CDEPT.4.2. Towards the discovery of new prodrug converting
enzymes (PCEs)Until 2006, the most studied nitroreductase for CB1954
prodrug activation was the E. coli NfnB (or EcoNTR) enzyme.
E. coli genes tend to be poorly expressed in clostridial hosts
due to differences in codon usage. Thus, in addition to the use
of more effective promoters, the codon optimisation of the
nfnB gene to suit the clostridial host has been shown to result
in improved expression and consequent increases in CB1954
conversion rates [46]. Other approaches to improve NfnB
involved altering its catalytic activity against prodrugs through
alterations to specific amino acid residues at the active site
using site-directed mutagenesis [51,52].
Table 1
A summary of genetically modified clostridial strains employed in anti-tumour studies until 2003.
Clostridium spp. Enzyme Prodrug/Drug Findings Reference
C. beijerinckii NCIMB 8052 Dihydropteridine
reductase (nfnB)a
CB1954 In vitro: 22-fold increase in tumour
cell eradication;
Lemmon 1997
In vivo: 10/10 EMT6 tumour bearing
mice were colonised with detectable
nitroreductase activity;
Cytosine deaminase
(codA)
5-fluorocytosie (5-FC)
converted to
5-fluorouracil (5-FU)
In vitro: 500-fold enhancement of
cytotoxicity towards murine tumour
cells
Fox 1996
In vivo: no anti-tumour effect
C. acetobutylicum strains
(DSM792 or NI4082)
Mouse tumour
necrosis factor alpha,
mTNFa
None Significant levels of biologically
active mTNF-a were measured in
both lysates and supernatants.
Theys 1999
None Combretastatin A-4 Improved colonisation in male
WAG/Rij rats bearing smaller than
1 cm3 tumours
Theys 2001
Cytosine deaminase
(codA)
5-fluorocytosie (5-FC)
converted to
5-fluorouracil (5-FU)
In vitro: The presence of CD gene
was confirmed and 5-FC conversion
detected
Theys 2001a
Cytosine deaminase
(codA) with vascular
targeting agent
CombreAp
In vivo: codA activity confirmed in
WAG/Rij rhabdomyosarcomas-
bearing rats and higher 5-FC
conversion rated detected
C. sporogenes NCIMB 10696 Cytosine deaminase
(codA)
5-fluorocytosie (5-FC)
converted to
5-fluorouracil (5-FU)
significant anti-tumour effect in
SCCVII-transplanted tumours in
C3H/Km mice
Liu 2002
Dihydropteridine
reductase (nfnB)
SN24927 Curative activity against WiDr
tumours in multi-layered tissue
culture model
Wilson 2002
Dihydropteridine
reductase (nfnB)
CB1954 reduced to
4-hydroxylamine in
combination with
DMXAA vascular
targeting agent
Expression of nfnB in tumour
confirmed with significant
anti-tumour efficacy;
Liu 2003
C. novyi-NT None Dolastatin-10 and
Combretastatin A-4
COBALT approach resulted in
significant tumour regression and
cure in 4 out of 8 HTC116 xenografts
Dang 2001
a In all cases where the gene in brackets was introduced, it was localised to an autonomous plasmid.
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led to the isolation of nitroreductases with a greater affinity for
CB1954 [39].
Out of fifteen proteins, two novel candidates (HinNTR
isolated from Haemophilus influenza and NmeNTR from
Neisseria meningitidies), which showed the best kinetic
properties, were selected. HinNTR was found to produce only
the 4-hydroxylamine (4-HX) derivative of CB1954 with a KM
and a kcat for this substrate of 690 mM and 56.2 s
1, respec-
tively, while NmeNTR has a lower KM of 2.47 and a kcat of
4.04 s1 [53]. These kinetic parameters mean that HinNTR
and NmeNTR more efficiently catalyse the conversion of
CB1954 than EcoNTR (NfnB), and thus represent superior
enzymes for use in CDEPT. In the context of clinically-
achievable concentration of CB1954, nitroreductase enzymes
with lower KM values will require small amount of this sub-
strate to approach saturation and therefore are more desirable.
Another enzyme reported to be an alternative candidate for
CB1954 bioactivation and the use in DEPT approaches, is the
YfkO nitroreductase from the thermophilic organism Bacillus
licheniformis [54]. The YfkO kcat for CB1954 was measured ata significantly high level (1.067  103 s1) and a KCB1954m was
found to be nearly 30-times lower (30 mM) than NfnB from E.
coli. The catalytic reaction of this nitroreductase with CB1954
resulted in production of the desired 4-HX product only.
Additionally, the enzyme was stable for more than 6 h at
temperatures up to 50 C, which may suggest extended ac-
tivity when used in targeted anti-cancer therapy.4.3. The first study of repeated CDEPT cyclesThe gene encoding HinNTR, named NTR-H in Theys
study, was codon optimised for Clostridium, cloned into an
expression vector and successfully conjugated into C. spor-
ogenes [38]. The in vivo experiments showed good, tumour-
specific germination and colonisation following recombinant
spore administration. Following administration of CB1954
tumour growth rates were reduced to nearly static levels in nu/
nu NMRI mice harbouring HCT116 tumours. This result
clearly demonstrates that spores of C. sporogenes could
deliver enough novel NTR-H enzyme to the tumour to convert
significant amounts of CB1954. Prodrug conversion translates
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recombinant C. sporogenes was tested in multiple consecutive
treatment cycles, interspersed with antibiotic-mediated bacte-
rial clearance. This strategy resulted in prolonged and signif-
icant anti-tumour effects when combined with CB1954
administration. The tumour only doubled in volume over the
course of a 70-day treatment, whereas the HCT116 control
doubled every 7 days. This study indicates that repeated cycles
of CDEPT can be administered which bodes well for future
clinical use. However, experiments involving immune-
competent animals are required to confirm its real-world ef-
ficacy [38].4.4. The integration of PCE genes into the clostridial
genomeUntil recently, the therapeutic genes of all the recombinant
clostridial strains tested have resided on autonomous plasmids
[38,55]. In the study of Heap et al., however, the therapeutic
gene used was stably integrated into the genome using Allele-
Coupled Exchange, or ACE [56]. This method is based on a
two-step recombination process during which the plasmid
vehicle and any encoded antibiotic resistance gene is elimi-
nated from the cell. Once integrated, the therapeutic gene is
stably maintained, minimising any risk both of its loss or of its
dissemination by horizontal gene transfer [56].
In the most recent CDEPT study, genes encoding a novel
NmeNTR enzyme and the previously studied NfnB were
codon optimised and integrated into the C. sporogenes
NCIMB 10696 genome at the pyrE locus using ACE [57].
pyrE encodes the pyrimidine biosynthesis enzyme, orotate
phosphoribosyltransferase. During the recombination event,
cells with inactivated pyrE were selected on growth medium
supplemented with 5-fluorooratic acid. This compound is
highly toxic to cells which contain this pathway, but is
harmless to cells without a functional pyrE. As a result, the
integrated strains were uracil auxotrophs.
In vitro experiments concluded that, aside from uracil
auxotrophy, all integrated NTR strains and the pyrE-negative
control strain behaved identically to the parent strain. Thus,
integration of the ntr gene had no impact on growth rate in
uracil deplete media, on spore formation or germination. It
follows that their potential use as tumour delivery vehicles has
not been in any way compromised by these genetic modifi-
cations. An in vivo study demonstrated that inactivation of the
pyrE gene did not affect the tumour colonising capacity of
systemically administered spores. Indeed, wild-type and pyrE
negative C. sporogenes colonised HCT116 xenografted tu-
mours equally well. On average 108e109 CFU were found per
gram of tumour tissue. As expected, C. sporogenes vegetative
cells were only present in tumours, and not in any other tissues
that were examined. Tumour growth data demonstrated that
NfnB- and NmeNTR-C. sporogenes integrants, in combination
with CB1954, had anti-tumour effects. The most promising
effect was observed with the strain producing NmeNTR. It
was estimated that the tumour growth rate remained static over
the first 25 days of observation, and in the following days,minimised to half of its initial size. After day 40, tumour re-
growth was observed [57]. This could be due to multiple
reasons, such as vegetative cell death, insufficient prodrug
concentration or poor enzyme expression.
5. The overview on the use of Clostridium spp. In other
anti-tumour strategies
In addition to CDEPT, other strategies are being explored
which combine the use of clostridial spores with various
different therapeutic options.5.1. Clostridium novyi-NTIn an alternative approach to CDEPT, Dang et al. (2001)
proposed the use of an attenuated strain of C. novyi-NT in
combination with conventional chemotherapeutical drugs for
the treatment of cancer (termed COBALT) [58]. The experi-
mental animals in their study suffered severe systemic toxicity,
and not all tumour types were found to be equally susceptible.
Subsequently, new approaches have been explored. In 2004,
the same research group studied the application of
microtubule-interacting chemotherapeutics alongside C.
novyi-NT spore administration [59]. Following simultaneous
treatment with bacterial spores and a novel anti-microtubule
destabiliser (HTI-286), which decreases the blood flow, an
enhanced haemorrhagic necrosis in all HCT116 xenografts
was observed. The long-term effects of the same therapy
tested on a range of different tumours were much less sig-
nificant, indicating strong tumour-type specificity. In the same
study, administration of two microtubule-stabilising drugs
(docetaxel and MAC-321) in combination with C. novyi-NT
resulted in gradual tumour regression. Most significantly,
complete cure of some experimental animals was achieved
with tumours measuring 100e250 mm3, and in others, the
duration of cancer remission was improved [59]. The apparent
curing of 4 out of 5 HCT116-bearing animals was also
recorded in other experiments on microtubule-stabilising ac-
tivity alongside C. novyi-NT treatment [60].
The use of C. novyi-NT spores has also been shown to
enhance the therapeutic effects when combined with radio-
therapy. As oxygen deprived cells are found to be more
resistant to radiation therapies, the use of anaerobic spore
treatment was thought to increase the tissue sensitivity to ra-
diation. In 2003, Bettegowda et al., conducted a study on three
major modes of radiation therapies: external beam, brachy-
therapy and radio-immunotherapy (RAIT), all combined with
the C. novyi-NT spore treatment [61]. The overall conclusion
of this work was that spores of C. novyi-NT demonstrated an
additive effect on tumour growth inhibition. For brachytherapy
specifically, only a single dose of spores resulted in 100% cure
of HCT116-bearing mice and HuCC-T1 xenografts. In addi-
tion, the administration of spores allowed the use of lower
doses of radiolabeled antibodies, resulting in a reduced toxic
effect on healthy tissues [61].
In 2006, the use of C. novyi-NT to aid the release of
liposomal drugs inside the tumour was explored [62]. This
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branes. It was hypothesised that germinated spores may assist
the release of liposome-encapsulated drugs at the tumour site.
This would result in an enhanced therapeutic effect. In their
study, Cheong and co-workers administered a single dose of
liposome-encased doxorubicin to tumour-bearing mice in
conjunction with C. novyi-NT spores. Tumour regression
occurred in all treated mice and 65% survived for 90
days [62].
The first experiment utilising C. novyi-NT and C. spor-
ogenes spores in combination with antibody treatment marked
the beginning of ‘Clostridium-directed antibody therapy’
(CDAT). In 2007, Groot et al. decided to focus on hypoxia-
inducible factor-1-alpha (HIF-1a), the activity of which is
associated with resistance to radio- and chemotherapy [63]. In
this study, Clostridium transconjugants were generated that
harboured plasmid with single chain 15 kDa VHH antibody
(specific towards HIF antigen). The in vitro experiment
confirmed that antibodies isolated from clostridia retained
their binding capacity and specificity towards the antigen. This
study demonstrates an early stage of the CDAT approach, and
it unveils new potential in combining antibody and clostridial-
based therapies.
More recently, C. novyi-NT spore treatment has been
evaluated in companion animals (dogs) with naturally occur-
ring tumours and, in a second study, in 16 dogs and one human
patient with an advanced and metastasised leiomysarcoma
(clinical trial identifier NCT01924689) [64,65]. In both
studies, a severe but manageable toxicosis and abscesses in
some treated canines were recorded. The authors report this
was most likely a consequence of an immune response or
hypersensitivity to the spores [64]. Crucially, the effectiveness
of clostridial spores in colonising naturally occurring tumours
was confirmed. During the phase 1 investigational study on the
human patient, the intra-tumourally administered treatment
resulted in a significant reduction at the tumour side and
surrounding of the bone. Unfortunately an adverse effect was
encountered, and the patient had to be treated for pathological
fracture of the right proximal humerus [65]. Such a case
demonstrates the potential challenges in C. novyi-NT-based
therapy, and that the efficacy and safety of this treatment needs
further attention.5.2. Clostridium perfringensAlthough normally associated with a food poisoning and
gas gangrene, C. perfringens is also able to selectively colo-
nise hypoxic tumours. Poorly vascularised hypoxic tissues of
pancreatic cancers have been put through an investigation
involving administration of C. perfringens spores [66]. In a
study by Li et al., C. perfringens strain was genetically
modified to eliminate a gene associated with oxygen tolerance
e superoxide dismutase. Further, it was recombined to express
Panton-Valentine Leukocidin (PVL) inflammation suppressive
gene [66]. It was hypothesised that the replication, and
therefore treatment efficacy of C. perfringens, can be
enhanced in tumour-bearing, immune-competent animalswhen their activity is suppressed. Indeed, the treatment of
mice with C. perfringens expressing the PVL cytotoxin
resulted in reduced inflammation, enhanced tumour necrosis
and prolonged survival (up to 120 days in 47% of experi-
mental animals). However, experiments were only designed
around one type of cancer and, unfortunately, in nearly half of
the animals, tumours recurred, causing death. Nevertheless,
the primary results are highly encouraging, and reveal a po-
tential for combining this treatment with more standard ap-
proaches, such as chemotherapy.
In several types of cancers, such as breast, ovarian or
pancreatic cancer, the expression of specific trans-membrane
proteins, called claudins (such as Cldn3 and Cldn4), was
found to be elevated. Their up-regulation is also correlated
with advanced stages and recurrence of prostate tumours.
Therefore, a novel approach of employing C. perfringens
enterotoxin (CPE) to bind to these proteins was explored. The
general mechanism of this selective gene therapy relies on
CPE binding to Cldn3 and Cldn4 receptors, resulting in pore
formation in epithelial cell membranes. The subsequent influx
of Ca2þ into the cell through these pores leads to cell death. In
the study by Maeda et al. (2012), Cldn3 and Cldn4 were
expressed in three primary human prostate cancers and normal
prostate tissues (PrEC) [67]. When CPE-mediated therapy was
employed, cytotoxic effects were found to be significant in
cancer cell lines, but only marginal in PrEC. Similar effects
were observed in the study of Walther and co-workers, which
utilised vector-based optimised CPE (optCPE) without
employing bacteria as a vector [68]. Additionally, an in vivo
experiment with this non-viral intra-tumoural gene transfer of
optCPE resulted in reduced tumour growth in breast and colon
cancer-bearing animals.
The targeted cytotoxicity of CPE observed in breast,
colon, prostate, pancreatic and ovarian cancer studies dem-
onstrates its positive potential [69e71]. Nevertheless, a lack
of indiscriminate toxicity and long-term efficacy should to be
demonstrated in vivo before considering C. perfringens
therapy for clinical use. As Cldn3 and 4 are also found in
some normal tissues, experiments on non-cancerous samples,
as well as the feasibility of gene transfer, need to be exam-
ined in greater detail. Moreover, it is widely accepted that
CPE is a major virulence factor, associated with common
bacterial food poisoning caused by the C. perfringens type A
strain, as well as other gastrointestinal diseases [72].
Although people can recover from poisoning within 24 h, for
some patients the illness can be fatal. The finding in one
study that 18% of screened healthy food handlers carry C.
perfringens suggests subclinical infection is common [73].
As a result, carriage of CPE antibody could be relatively high
in the general public. This may cause an undesirable immune
response to be elicited in potential cancer patients treated
with the CPE therapy. While non-pathogenic options exist,
treatment regimes using C. perfringens are unlikely to be
preferred. The use of any microbe in a clinical setting is
controversial and, therefore, the use of a strain or its toxin
that have been established as pathogenic would likely face
substantial resistance.
251A.M. Kubiak, N.P. Minton / Research in Microbiology 166 (2015) 244e2545.3. Clostridium acetobutylicumIn the pursuit of a clostridia-mediated cancer treatment,
saccharolytic strains of clostridia have also been investigated.
Strains of C. beijerinckii, C. acetobutylicum and Clostridium
saccharoperbutyliacetonicum were used, not only to express
PCEs but also other molecules with cytotoxic activity against
tumours. In the study by Theys et al. (1999), a non-pathogenic
C. acetobutylicum, strain DSM792, was used initially to secret
murine tumour necrosis factor (mTNF-a) [74]. This is a
cytokine known to stimulate accumulation of macrophages,
neutrophiles and T cells, and therefore indirectly triggers anti-
tumour responses. However, injection of recombinant C.
acetobutylicum producing mTNF-a did not result in a signif-
icant delay of tumour growth. Another cytokine, rat-derived
interleukin-2 (IL-2), was tested and shown to have a much
greater effect on tumour regression. This was studied in work
of Barbe et al. in 2005 [75]. The plasmid-based rIL-2 was
expressed by C. acetobutylicum and its biological function-
ality was confirmed. When spores of the therapeutic strain
were intra-tumourally administered to rhabdomyosarcoma-
bearing rats in combination with fractionated radiotherapy,
significant tumour regression was observed. This was due to
the increased activity of immune cells. The rIL-2 injected on
its own, as a purified protein solution, did not have the same
effect, suggesting the importance of supplying the cytokine in
a clostridial vehicle [75].
Despite the efforts of employing saccharolytic clostridia, it
is believed that the use of more effective colonisers, such as C.
sporogenes, would be more advantageous in cytokine-based
approaches. The verification of interleukin activity, once in-
tegrated into the bacterial chromosome, would bring further
confirmation of the feasibility of these strategies.
6. Imaging tumour-localised clostridia and other bacteria
Evaluation of clostridial colonisation and distribution
within the tumour mass would benefit from an easily acces-
sible and non-invasive imaging methodology. In the past
decade, a number of options have been explored to visualise
colonisation in tumour-bearing hosts [76e78]. Although the
studies conducted focused on bacteria such as Salmonella
typhimurium and E. coli, their findings could potentially be
adapted to clostridial-based strategies.
Genes that encode light-emitting fluorescent proteins or
luciferases have been employed to detect bacteria injected into
experimental animals. In the study by Yu et al., a lux-GFP
fusion complex was expressed in three attenuated pathogens
(S. typhimurium, Listeria monocytogenes, Vibrio choleare) and
E. coli [79]. Each bacterium were injected separately into C6
glioma-bearing, breast tumour nude mice and monitored for
movements from the injection site to the tumours. It was found
that all bacteria entered and replicated in primary as well as
metastasised tumours. In addition, further experiments have
shown that immune-competent animals were colonised
equally well [79]. This real-time imaging could potentially be
applied to a clostridial host, providing the in-host functionalityof light-emitting proteins. As such, it has been suggested that
oxygen-independent fluorescent molecules could potentially
offer a solution to visual tracking of clostridial colonisers [80].
Another strategy involves the application of nuclear imag-
ing techniques, such as positron emission tomography (PET)
or single-photon emission computed tomography (SPECT).
Liu et al. investigated whether endogenous bacterial enzymes,
such as thymidine kinase (TK), could react with radio-labelled
substrates to produce a radio-detectable reaction [81]. In this
work, C. novyi-NT spores (amongst other bacteria) were used
to colonise CT-26 colon tumour-bearing mice. After 24 h,
radio labelled 1-(20-deoxy-20-fluoro-b-D-arabinofuranosyl)-5-
iodouracil (FIAU) was administered via a tail vein, and
imaged at various time points using SPECT. The overall re-
sults confirmed the uptake of the [125I]FIAU probe inside the
tumour. Uptake was observed as early as 16 h post-injection,
peaking at 24e48 h. No uptake was detected in animals not
treated with C. novyi-NT. Similar results were confirmed in
tumour-bearing rabbits in which the uptake of probe was only
recorded alongside tumour-limited bacterial germination using
SPECT/CT cameras. These findings suggest that the presence
of endogenous TKs in clostridial species can offer a solution to
nuclear imaging techniques. More recently, the utilisation of a
chemical exchange saturation transfer (CEST) MRI method
for imaging intra-tumoural bacterial colonisation was
demonstrated. This method relies on the chemical exchange
between an exchangeable proton and its surrounding water
protons, in order to transfer the selectively modified NMR
signal and produce an MRI image. Germinating bacteria
produce a range of macromolecules and metabolites, and by
interacting with surrounding water protons, they can be
detected through their differential endogenous CEST contrast.
Liu et al., tested this approach on C. novyi-NT and named it
‘bacCEST’ [81]. At first, the endogenous CEST contrast of
vegetative C. novyi-NT was assessed in vitro and compared to
the spore profile. It was shown that spores produced no
detectable CEST signal. This is likely to be a consequence of
the low water content in the spore, and the thick coat sur-
rounding, as well as a lack of metabolic activity. Further ex-
periments involved monitoring the CEST signal before and
after systemic spore injection in colon tumour-bearing mice.
The results obtained confirmed visible CEST changes relating
to bacterial infiltration, in contrast to images of pre-injected
tumours. In addition, a preliminary assessment was made of
the influence of a number of different factors and it was
concluded that the profile of CEST contrast wasn't signifi-
cantly altered by stimulated changes in pH, local inflammation
or necrosis. These findings illustrate that bacCEST imaging
can be successfully employed in clostridial-based therapies.
7. Conclusions
It is now over eighty years since the concept of using
clostridia to treat cancer emerged, but it is only in the last
decade that meaningful progress towards this goal has been
made. Much of this headway has been driven by the devel-
opment of more sophisticated gene technologies with which
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required therapeutic attribute. The vast majority of engineered
strains used to date in proof of principle studies have, however,
used strains endowed with autonomous plasmids which carry
antibiotic resistance genes. It follows that the engineered traits
are segregationally unstable. Moreover, the use of plasmids is
unacceptable from a regulatory perspective. The required
modifications, therefore, need to be stably introduced into the
bacterial genome. This has now been made possible by the
development of Allele-Coupled Exchange (ACE) technology
[56], a procedure capable of introducing DNA of any size or
complexity into clostridial genomes. Indeed, ACE was used to
create a CDEPT strain that was used in a mouse xenograft
model of human colon carcinoma to achieve substantial
tumour suppression, and in some cases cure [57]. Following
these encouraging data and the creation of clinically relevant
strains, it is anticipated that CDEPT will shortly enter clinical
trials. In the meantime the encouraging results of the studies
with C. novyi-NT spore treatment [64,65], underlines the fact
that clostridia species seem destined to have a significant role
to play in the future treatment of solid tumours.
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